| Carla Vonneumann-lillie, | |
|
7300 Yountville Dr., 203, Gainesville, VA 20155-3442 | |
| (571) 379-6063 | |
| Not Available |
| Full Name | Carla Vonneumann-lillie |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 7300 Yountville Dr., Gainesville, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982390878 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | 0002086039 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Carla Vonneumann-lillie, 7300 Yountville Dr Apt 203, Gainesville, VA 20155-3442 Ph: (571) 379-6063 | Carla Vonneumann-lillie, 7300 Yountville Dr., 203, Gainesville, VA 20155-3442 Ph: (571) 379-6063 |
News Archive
The amount of time a person sits during the day is associated with a higher risk of heart disease, diabetes, cancer, and death, regardless of regular exercise—according to a review study published today in the Annals of Internal Medicine.
Oraya Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD).
New research published in the International Journal of Toxicology (IJT) by Gary S. Goldman, Ph.D., reveals high rates of shingles (herpes zoster) in Americans since the government's 1995 recommendation that all children receive chicken pox vaccine.
New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, shows that an artificial intelligence-based analysis model, called an artificial neural network, enables accurate detection of definite radiographic sacroiliitis in people with axial spondyloarthritis, an advance that could be useful for both diagnosis in the clinic and classification of patients for inclusion in clinical trials.
GENova Biotherapeutics Inc. ("GENova") today announced it has signed an LOI with Prime BioResearch, Ltd. ("Prime BioResearch"), another drug acquisition company in the areas of drug development and distribution a business case that will save GENova millions every year in drug development and at the same time more than double GENova's distribution network enabling GENova to potentially exceed its own expectations of reaching 100m+ in revenue in year.
› Verified 9 days ago